Asahi Kasei Commences Tender Offer for Shares of Veloxis Pharmaceuticals A/S
Asahi Kasei Corp.
Related to the prior release, “Asahi Kasei to Acquire Veloxis Pharmaceuticals Inc.”, announced on November 25, 2019, Asahi Kasei Corp. (Head office: Chiyoda-ku, Tokyo; President: Hideki Kobori) announced today that its wholly owned subsidiary, Asahi Kasei Pharma Denmark A/S, commenced on December 12, 2019 (CET) a tender offer for the shares and warrants in Veloxis Pharmaceuticals A/S (Head office: Copenhagen, Denmark; CEO: Craig A. Collard; listed on Nasdaq Copenhagen; hereinafter “Veloxis DK”), which owns 100% of Veloxis Pharmaceuticals Inc. (Head office: North Carolina, the U.S.; CEO: Craig A. Collard) (the tender offer pursuant to Danish Laws, “the Tender Offer”).
The Tender Offer is open for tenders as of December 12, 2019 and expected to expire on January 14, 2020 at 5:00 p.m. (CET). In accordance with the agreement with Veloxis DK, the offer period may be extended in the event that any of the conditions of the Tender Offer have not been satisfied.